# A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

> **NCT00297362** · — · COMPLETED · sponsor: **Janssen Cilag Pharmaceutica S.A.C.I., Greece** · enrollment: 344 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Galantamine hydrobromide

## Key facts

- **NCT ID:** NCT00297362
- **Lead sponsor:** Janssen Cilag Pharmaceutica S.A.C.I., Greece
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2012-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00297362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00297362, "A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00297362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*